SAN FRANCISCO, Aug. 29, 2016 – Symic, a clinical stage biotherapeutics company developing therapies inspired by naturally occurring molecules ofREAD MORE…
At Russo Partners, communications counselors with PhDs, MDs, JDs and MBAs roll up their sleeves to implement integrated programs for biopharma, medtech, diagnostics, healthcare IT and healthcare services companies worldwide.
Since our founding as Noonan/Russo more than 25 years ago, we’ve been on a first-name basis with the people you need to be talking to. Which means you should be talking to us.
Cynapsus Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson’s Disease
AUGUST 29, 2016 Company provides timing updates TORONTO, Aug. 29, 2016 (GLOBE NEWSWIRE) — Cynapsus Therapeutics Inc. (NASDAQ:CYNA) (TSX:CTH), todayREAD MORE…
DalCor Announces Opening of International Trial Sites for Its Dal-GenE Phase 3 Cardiovascular Outcomes Trial
Sites open in Europe and New Zealand Enrollment on schedule in trial of dalcetrapib in genetically distinct patients with acuteREAD MORE…